ArticleCurrent pharmaceutical design2011
The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention.
Article in Current pharmaceutical design, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Antioxidants & redox signaling · 2014Trial
- Recapitulation of plaque formation, tau pathology, and neurodegeneration in a human 3D matrix model of Alzheimer's disease.Cell reports methods · 2026Article
- Mitochondrial Fragmentation as a Key Driver of Neurodegenerative Disease.Current Alzheimer research · 2024Review
- Cerebral oxygen metabolism from MRI susceptibility.NeuroImage · 2023Review
- Ferroptosis as a Major Factor and Therapeutic Target for Neuroinflammation in Parkinson's Disease.Biomedicines · 2021Review
- Gene network analysis to determine the effect of hypoxia-associated genes on brain damages and tumorigenesis using an avian model.Journal, genetic engineering & biotechnology · 2021Article
- Mitochondrially-Targeted Therapeutic Strategies for Alzheimer's Disease.Current Alzheimer research · 2021Review
- Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria.Ageing research reviews · 2021Review
- Obesity and Diabetes Mediated Chronic Inflammation: A Potential Biomarker in Alzheimer's Disease.Journal of personalized medicine · 2020Review
- Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.Cells · 2019Review
- A reciprocal relationship between reactive oxygen species and mitochondrial dynamics in neurodegeneration.Redox biology · 2018Article
- Time to get Personal: A Framework for Personalized Targeting of Oxidative Stress in Neurotoxicity and Neurodegenerative Disease.Current opinion in toxicology · 2018Article
- Mitochondria and Alzheimer's Disease: the Role of Mitochondrial Genetic Variation.Current genetic medicine reports · 2018Review
- Dietary Restriction and AMPK Increase Lifespan via Mitochondrial Network and Peroxisome Remodeling.Cell metabolism · 2017Article
- Relationship Between β-Amyloid and Mitochondrial Dynamics.Cellular and molecular neurobiology · 2017Review
- Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease.Drug design, development and therapy · 2017Review
- Novel super-resolution capable mitochondrial probe, MitoRed AIE, enables assessment of real-time molecular mitochondrial dynamics.Scientific reports · 2016Article
- Cytoplasmic irradiation results in mitochondrial dysfunction and DRP1-dependent mitochondrial fission.Cancer research · 2013Article
- The role of mitochondria in the development and progression of lung cancer.Computational and structural biotechnology journal · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Mitochondrial dynamics play a crucial role in the pathobiology underlying Alzheimer's disease (AD) and Parkinson's disease (PD). Although a complete scientific understanding of these devastating conditions has yet to be realized, alterations in mitochondrial fission and fusion, and in the protein complexes that orchestrate mitochondrial fission and fusion, have been well established in AD- and PD-related neurodegeneration. Whether fission/fusion disruption in the brain is a causal agent in neuronal demise or a product of some other upstream disturbance is still a matter of debate; however, in both AD and PD, the potential for successful therapeutic amelioration of degeneration via mitochondrial protection is high. We here discuss the role of mitochondrial dynamics in AD and PD and assess the need for their therapeutic exploitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.